Clinical Trials Logo

KRAS G12D clinical trials

View clinical trials related to KRAS G12D.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04853017 Active, not recruiting - Colorectal Cancer Clinical Trials

A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors

AMPLIFY-201
Start date: October 4, 2021
Phase: Phase 1
Study type: Interventional

This is a Phase 1 study to assess the safety and efficacy of ELI-002 immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide [Amph-CpG-7909] plus a mixture of lipid-conjugated peptide-based antigens [Amph-Peptides]) as adjuvant treatment of minimal residual disease (MRD) in subjects with KRAS/neuroblastoma ras viral oncogene homolog (NRAS) mutated PDAC or other solid tumors.